CompletedNot Applicable

Anticoagulation in Emergency General Surgery

United States4 participantsStarted 2019-10-31

Plain-language summary

While DOACs are increasing in use in the EGS patient population, the risk of bleeding and the reversal of these agents to reduce hemorrhage is still evolving. Given the paucity of data regarding the impact of DOACs in this patient population, it becomes empiric to identify bleeding patterns and outcomes in the EGS population taking DOACs. We hypothesize that patients taking a DOAC will have a higher bleeding incidence and need for an unplanned intervention secondary to hemorrhage in EGS patients undergoing an urgent or emergent operation when compared to patients taking warfarin and antiplatelets.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients who are confirmed to be taking dabigatran, rivaroxaban, apixaban, warfarin and antiplatelet therapy (aspirin, clopidogril, ticagrelor) undergoing an urgent or emergent surgical intervention by the emergency general surgery service within 24 hours of arrival to the hospital * 18 years of age or over Exclusion Criteria: * Prisoners * Pregnant patients * Those who received an index operation at an outside facility and were transferred * Under 18 years of age

What they're measuring

Rate of operative

Timeframe: Oct 2019 - Aug 2021

Number of Participants with interventional radiology

Timeframe: Oct 2019 - Aug 2021

Number of Participants with ultrasound aspiration

Timeframe: Oct 2019 - Aug 2021

Trial details

NCT IDNCT04216394

SponsorMethodist Health System

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-11-13

View on ClinicalTrials.gov More Emergency General Surgery trials